Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03755804 · ClinicalTrials.gov registry record · Phase 2
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
A Phase 2 study of Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 232
- Enrollment target
- 8
- Study locations
NCT03755804 is a Phase 2 study of Hodgkin Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 232 participants, above the 163-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (42% higher). The trial reports 8 study locations across 7 states.
The verdict
NCT03755804, a Phase 2 study of Hodgkin Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 232 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Etoposide
- DRUG Vincristine
- DRUG Bleomycin
- DRUG bendamustine
Study Locations (8)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
California
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Illinois
- St. Jude Midwest Affiliate - Peoria - Peoria
Louisiana
- St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center) - Baton Rouge
Maine
- Maine Children's Cancer Program - Scarborough
North Carolina
- St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital - Charlotte
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03755804
The ClinicalTrials.gov registry entry for NCT03755804 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 163-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (42% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT03755804 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03755804 about?
NCT03755804 is a clinical study titled "Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17". This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubic...
What is the current status of trial NCT03755804?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 232 participants. The study started on 2018-12-12. Estimated completion is 2028-07-01.
What conditions does trial NCT03755804 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT03755804?
The interventions under investigation include: Doxorubicin (DRUG), Etoposide (DRUG), Vincristine (DRUG), Bleomycin (DRUG), bendamustine (DRUG).
Who is sponsoring clinical trial NCT03755804?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03755804 being conducted?
This trial has 8 study locations across California, Illinois, Louisiana, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.